Overview
The National Lung Screening Trial provided clear evidence of a lung cancer mortality reduction in high-risk patients who undergo screening with low-dose CT. This has changed clinical guidelines and radically influenced health care policy, for the first time offering early detection for the largest cause of cancer death. Debate continues about optimal selection criteria for screening, and minimizing the unintended harms of early detection. The institution of lung cancer screening affords the largest opportunity for cancer death reduction in a generation, yet requires thoughtful implementation with expertise in evaluation and management of screen-detected abnormalities. In this program we will address these and other related issues. The Goal & Purpose of this activity is:
- Recognize the current status of Lung Cancer Screening clinical guidelines in the United States.
- Identify the challenges of implementing Lung Cancer Screening in clinical practice.
- Illustrate the evaluation and management of screen - detected abnormalities.
After attending this activity, participants will be able to:
- Provide clear direction as to optimal selection criteria of patients for screening.
- Educate clinicians as to the implementation of lung cancer screening.
- Review The National Lung Screening Trial that provides clinical evidence of a lung cancer mortality reduction in high-risk patients who undergo screening with low-dose CT.
- Recognize recently changed clinical guidelines that (for the first time) support early detection of lung cancer.
Douglas E. Wood, MD
The Henry N. Harkins Professor and Chair, Department of Surgery, University of Washington.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.
After attending this activity, participants will be able to:
- Provide clear direction as to optimal selection criteria of patients for screening.
- Educate clinicians as to the implementation of lung cancer screening.
- Review The National Lung Screening Trial that provides clinical evidence of a lung cancer mortality reduction in high-risk patients who undergo screening with low-dose CT.
- Recognize recently changed clinical guidelines that (for the first time) support early detection of lung cancer.
Douglas E. Wood, MD
The Henry N. Harkins Professor and Chair, Department of Surgery, University of Washington.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.